Back to the Homepage
 |
||
 Hemi-synthetic homoharringtonine is still not marketed. It is commonly prescribed for compassionate use in France, to named patients.Based on the product extensive bibliography, an orphan drug status was obtained for Europe in 2004 in chronic myeloid leukeamia (CML) and in acute myeloid leukeamia (AML) indications, and submissions are in preparation for the USA. |
||
 |
||
Back to the Homepage